• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

    6/10/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email

    Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing

    On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities

    BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company's Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches.

    Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in June 2025. Dr. Verwijs was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA and commercial launch. With a focus on drug product and process development, scale-up and validation, he has extensive expertise leading all CMC functions, including overseeing the supply chain and quality assurance. He has held leadership positions of increasing responsibility at several prominent Boston biotech companies including Aerovate, Epizyme, Flexion and Vertex.

    "We are pleased to welcome Dr. Verwijs to our leadership team as we embark on the next steps in the neflamapimod development pathway," said John Alam, MD, Chief Executive Officer of CervoMed. "We believe that Marco will serve a pivotal function in assuring product quality as we advance neflamapimod into Phase 3 in dementia with Lewy Bodies (DLB) in mid-2026 and prepare for future regulatory filings and potential commercial launch. We look forward to leveraging his impressive skill set at this critical juncture for the Company as we prepare to initiate the Phase 3 pivotal trial in DLB."

    Inducement Grants

    On June 9, 2025, CervoMed granted Dr. Verwijs an option to purchase an aggregate of 54,000 shares of CervoMed common stock with an exercise price of $7.74, the closing price of the Company's common stock on the grant date. The option will vest in 36 equal installments on the last day of each month over a three-year period commencing June 30, 2025, subject to the employee's continued employment with the Company on each such date. The award was approved by the compensation committee of the Company's board of directors as an inducement material to Dr. Verwijs entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

    About CervoMed

    CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

    Forward-Looking Statements

    This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the Company's financial position and cash runway, the therapeutic potential of neflamapimod, the anticipated timing and achievement of clinical and development milestones, including the completion the RewinD-LB Phase 2b clinical trial and the Company's announcement of additional data therefrom, any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the AscenD-LB trial or RewinD-LB trial will be replicated in later trials, and the timing of the initiation of any potential future trials or interactions with regulatory authorities, including the Company's need to acquire sufficient funding prior to initiating any Phase 3 trial of neflamapimod in DLB. Terms such as "believes," "estimates," "anticipates," "expects," "plans," "aims," "seeks," "intends," "may," "might," "could," "might," "will," "should," "approximately," "potential," "target," "project," "contemplate," "predict," "forecast," "continue," or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company's control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company's available cash resources and the availability of additional funds on acceptable terms; the results of the Company's clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

    Investor Contact:

    PJ Kelleher

    LifeSci Advisors

    [email protected]

    617-430-7579



    Primary Logo

    Get the next $CRVO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    9/18/2024$55.00Buy
    Chardan Capital Markets
    More analyst ratings

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

      Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company's Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches. Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical O

      6/10/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financia

      5/12/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

      BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 5:00 – 5:30 PM ETWebcast Link: https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website htt

      5/7/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CervoMed upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

      3/13/25 7:28:49 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by H.C. Wainwright

      H.C. Wainwright downgraded CervoMed from Buy to Neutral

      12/17/24 7:40:50 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded CervoMed from Buy to Neutral

      12/11/24 7:28:58 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO & President Alam John J

      4 - CervoMed Inc. (0001053691) (Issuer)

      6/25/25 5:05:20 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Zavrl Frank

      4 - CervoMed Inc. (0001053691) (Issuer)

      6/25/25 5:04:25 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Boger Joshua S

      4 - CervoMed Inc. (0001053691) (Issuer)

      6/25/25 5:03:28 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Financials

    Live finance-specific insights

    See more
    • CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

      A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

      3/10/25 4:05:00 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    SEC Filings

    See more
    • CervoMed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CervoMed Inc. (0001053691) (Filer)

      6/25/25 5:10:53 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CervoMed Inc. (0001053691) (Filer)

      5/19/25 4:08:01 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by CervoMed Inc.

      424B5 - CervoMed Inc. (0001053691) (Filer)

      5/12/25 5:13:43 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO, GC & Secretary Elder William Robert bought $35,811 worth of shares (4,233 units at $8.46), increasing direct ownership by 334% to 5,500 units (SEC Form 4)

      4 - CervoMed Inc. (0001053691) (Issuer)

      5/14/25 4:11:47 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

      4 - CervoMed Inc. (0001053691) (Issuer)

      8/27/24 4:09:50 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      11/14/24 3:09:10 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      4/11/24 7:55:23 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

      SC 13G/A - CervoMed Inc. (0001053691) (Subject)

      3/6/24 4:05:55 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    See more
    • CervoMed to Appoint William Elder as Chief Financial Officer

      BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

      5/20/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

      - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

      4/1/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

      Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

      2/7/24 8:30:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care